Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen, J&J Revise Labels For Aranesp, Epogen, Procrit

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen says it will present new data to CMS in effort to persuade agency to modify its National Coverage Decision on ESAs.

You may also be interested in...



J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market

Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.

J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market

Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.

European Regulators Approve Labeling Update For Amgen’s Aranesp

Revised European ESA prescribing information consistent with proposal released last fall.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel